linkedin

Jurisprudence

You will find here a selection of decisions of the French Courts, of the European patent Office (EPO) and of the European Union Intellectual property Office(EUIPO). Various teams of CASALONGA were involved in some of the cases handled. Other cases are quoted here in view of their particular importance.

Paris Court of Appel - SAS MAISONS DU MONDE France v/ SA LEROY MERLIN, SAS BENOIT LE TAPIS BROSSE & SAS ALSAPAN

2021-06-15


LEROY MERLIN was represented by Arnaud CASALONGA, Attorney at Law.

Considering that a doormat and a range of industrial style furniture commercialized by LEROY MERLIN and BENOIT LE TAPIS BROSSE reproduced the combination of the distinctive elements of its "Atelier" doormat model and its "Docks" range of furniture, MAISONS DU MONDE sued SA LEROY MERLIN, SAS BENOIT LE TAPIS BROSSE & SAS ALSAPAN before the Paris Commercial Court on the ground of unfair competition and parasitism.

By a judgment rendered on April 8, 2019, the Paris Commercial Court ruled against LEROY MERLIN and BENOIT LE TAPIS BROSSE on the basis of unfair competition for the doormat model but dismissed MAISONS DU MONDE’s claims relating to the industrial furniture.

In its decision of June 15, 2021, the Court of Appeal of Paris rejected all the claims of MAISONS DU MONDE on both unfair competition and parasitism.

On unfair competition: MAISONS DU MONDE argued that there was a likelihood of confusion between its doormat and furniture and those commercialized by LEROY MERLIN. First, (...)

Paris Court of Appeal - SAS BIOGARAN v/ DAIICHI SANKYO COMPANY LIMITED, M. le Directeur général de l’INPI, SAS TEVA SANTE & SAS EG LABO - LABORATOIRES EUROGENERICS

2021-05-21


BIOGARAN was represented by Arnaud CASALONGA and Floriane CODEVELLE, Attorneys at Law (Paris bar).
In its very clear decision issued on May 21, 2021, the Paris Court of Appeal marks a real turning point in a legal saga that has lasted for decades between the company BIOGARAN and other generic pharmaceuticals on the one hand, and DAIICHI on the other.

In its decision of May 21, 2021, the Paris Court of Appeal ruled that the third-party opposition filed by BIOGARAN was admissible and well-founded, and retracted the decision (...)